These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 1830302)

  • 21. Patterns and mechanisms of emergence of resistance to amikacin.
    Meyer RD
    J Infect Dis; 1977 Sep; 136(3):449-52. PubMed ID: 409785
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vivo study assessed meropenem and amikacin combination therapy against carbapenem-resistant and carbapenemase-producing Enterobacteriaceae strains.
    Hagihara M; Kato H; Yamashita R; Soda M; Watanabe H; Sakanashi D; Shiota A; Asai N; Koizumi Y; Suematsu H; Yamagishi Y; Kitaichi K; Mikamo H
    J Infect Chemother; 2020 Jan; 26(1):1-7. PubMed ID: 31735629
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Elucidation of the pharmacokinetic/pharmacodynamic determinant of colistin activity against Pseudomonas aeruginosa in murine thigh and lung infection models.
    Dudhani RV; Turnidge JD; Coulthard K; Milne RW; Rayner CR; Li J; Nation RL
    Antimicrob Agents Chemother; 2010 Mar; 54(3):1117-24. PubMed ID: 20028824
    [TBL] [Abstract][Full Text] [Related]  

  • 24.
    Lepak AJ; Zhao M; VanScoy B; Taylor DS; Ellis-Grosse E; Ambrose PG; Andes DR
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28396549
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative study of the serum bactericidal activity of cefoperazone alone and in combination with amikacin or mezlocillin against gram-negative bacilli and Staphylococcus aureus.
    Lagast H; Klastersky J; Standiford H; Viollier A
    Infection; 1984; 12(3):190-3. PubMed ID: 6432702
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacodynamics of the new fluoroquinolone gatifloxacin in murine thigh and lung infection models.
    Andes D; Craig WA
    Antimicrob Agents Chemother; 2002 Jun; 46(6):1665-70. PubMed ID: 12019073
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro activity of newer beta-lactam agents in combination with amikacin against Pseudomonas aeruginosa, Klebsiella pneumoniae, and Serratia marcescens.
    Meyer RD; Pasiecznik K
    Diagn Microbiol Infect Dis; 1983 Dec; 1(4):287-93. PubMed ID: 6321092
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In-vitro activity of ceftolozane/tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae isolates recovered from hospitalized patients in Germany.
    Seifert H; Körber-Irrgang B; Kresken M;
    Int J Antimicrob Agents; 2018 Feb; 51(2):227-234. PubMed ID: 28705666
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacodynamics of Aerosolized Fosfomycin and Amikacin against Resistant Clinical Isolates of Pseudomonas aeruginosa and Klebsiella pneumoniae in a Hollow-Fiber Infection Model: Experimental Basis for Combination Therapy.
    Sime FB; Johnson A; Whalley S; Santoyo-Castelazo A; Montgomery AB; Walters KA; Lipman J; Hope WW; Roberts JA
    Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27795380
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Determination of optimal dosage regimen for amikacin in healthy volunteers by study of pharmacokinetics and bactericidal activity.
    Garraffo R; Drugeon HB; Dellamonica P; Bernard E; Lapalus P
    Antimicrob Agents Chemother; 1990 Apr; 34(4):614-21. PubMed ID: 2111658
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of Amikacin in a hospital for children: microbiological and clinical studies.
    Marget W; Reindke B; Versmold H
    J Infect Dis; 1976 Nov; 134 SUPPL():S412-9. PubMed ID: 825592
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adaptive resistance of Pseudomonas aeruginosa induced by aminoglycosides and killing kinetics in a rabbit endocarditis model.
    Xiong YQ; Caillon J; Kergueris MF; Drugeon H; Baron D; Potel G; Bayer AS
    Antimicrob Agents Chemother; 1997 Apr; 41(4):823-6. PubMed ID: 9087497
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Empirical monotherapy with meropenem or combination therapy: the microbiological point of view.
    Garcinuño P; Santibañez M; Gimeno L; Sánchez-Bautista A; Coy J; Sánchez-Paya J; Boix V; Merino E; Portilla J; Rodríguez JC
    Eur J Clin Microbiol Infect Dis; 2016 Nov; 35(11):1851-1855. PubMed ID: 27503076
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bactericidal efficacy of Sch 20569 and amikacin against gentamicin-sensitive and -resistant organisms.
    Rahal JJ; Simberkoff MS; Kagan K; Moldover NH
    Antimicrob Agents Chemother; 1976 Apr; 9(4):595-9. PubMed ID: 817661
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of clindamycin on the in vitro activity of amikacin and gentamicin against gram-negative bacilli.
    Zinner SH; Provonchee RB; Elias KS; Peter G
    Antimicrob Agents Chemother; 1976 Apr; 9(4):661-4. PubMed ID: 817663
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacodynamics of inhaled amikacin (BAY 41-6551) studied in an in vitro pharmacokinetic model of infection.
    Bowker KE; Noel AR; Tomaselli S; Attwood M; MacGowan AP
    J Antimicrob Chemother; 2018 May; 73(5):1305-1313. PubMed ID: 29562340
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Amikacin therapy for severe gram-negative sepsis. Emphasis on infections with gentamicin-resistant organisms.
    Tally FP; Louie TJ; Weinstein WM; Bartlett JG; Gorbach SL
    Ann Intern Med; 1975 Oct; 83(4):484-8. PubMed ID: 1101761
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antimicrobial Activity of Ceftolozane-Tazobactam Tested Against Enterobacteriaceae and Pseudomonas aeruginosa with Various Resistance Patterns Isolated in U.S. Hospitals (2013-2016) as Part of the Surveillance Program: Program to Assess Ceftolozane-Tazobactam Susceptibility.
    Shortridge D; Pfaller MA; Castanheira M; Flamm RK
    Microb Drug Resist; 2018 Jun; 24(5):563-577. PubMed ID: 29039729
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacodynamics of ceftazidime administered as continuous infusion or intermittent bolus alone and in combination with single daily-dose amikacin against Pseudomonas aeruginosa in an in vitro infection model.
    Cappelletty DM; Kang SL; Palmer SM; Rybak MJ
    Antimicrob Agents Chemother; 1995 Aug; 39(8):1797-801. PubMed ID: 7486921
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bactericidal activity and killing rate of serum from volunteers receiving pefloxacin alone or in combination with amikacin.
    Van der Auwera P; Klastersky J; Lieppe S; Husson M; Lauzon D; Lopez AP
    Antimicrob Agents Chemother; 1986 Feb; 29(2):230-4. PubMed ID: 3087276
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.